Alalevonadifloxacin Explained

Drug Name:	Alalevonadifloxacin
Tradename:	Emrok O
Routes Of Administration:	Oral
Legal Status:	Rx in India
Cas Number:	706809-20-3
Pubchem:	16734914
Chemspiderid:	19538972
Iuphar Ligand:	10756
Unii:	57B7E1D1TG
Chembl:	5095635
Iupac Name:	(12S)-8-[4-[(2''S'')-2-Aminopropanoyl]oxypiperidin-1-yl]-7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.0<sup>5,13</sup>]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
C:	22
H:	26
F:	1
N:	3
O:	5
Smiles:	C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)OC(=O)[C@H](C)N)F)C(=O)O
Stdinchi:	InChI=1S/C22H26FN3O5/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24/h9-13H,3-8,24H2,1-2H3,(H,28,29)/t11-,12-/m0/s1
Stdinchikey:	OUXXDXXQNWKOIF-RYUDHWBXSA-N

Alalevonadifloxacin (trade name Emrok O) is an antibiotic of the fluoroquinolone class.^[1] It is a prodrug of levonadifloxacin with increased oral bioavailability.^[2] In India, it is approved for the treatment of infections with Gram-positive bacteria.^[3]

Notes and References

Saseedharan S, Dubey D, Singh RK, Zirpe K, Choudhuri AH, Mukherjee DN, Gupta N, Sahasrabudhe S, Soni S, Kulkarni S, Walse P, Vora AC, Thomas J, Tayade A, Bhadarke G, Kishore K, Paliwal Y, Patil P, Reddy PK, Nagvekar V, Veeraraghavan B . Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral) . Indian Journal of Medical Microbiology . 47 . 100528 . 2024 . 38228227 . 10.1016/j.ijmmb.2024.100528 . free .
Bhawsar S, Kale R, Deshpande P, Yeole R, Bhagwat S, Patel M . Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection . Bioorganic & Medicinal Chemistry Letters . 54 . 128432 . December 2021 . 34757217 . 10.1016/j.bmcl.2021.128432 .
Web site: Alalevonadifloxacin . AdisInsight . Springer Nature Switzerland AG .